EULA Home Care Agency Reaffirms Commitment to Provide Senior Home Care in Harrisburg
EULA Home Care Agency reaffirms its commitment to senior care in Harrisburg, NC, ensuring aging residents have access to compassionate, personalized in-home support. The agency's professional caregivers assist with daily tasks, mobility, and companionship, helping seniors live independently while giving families peace of mind. With a growing senior population, EULA continues to be a trusted resource for reliable, dignified care rooted in community values.
Harrisburg, NC - EULA Home Care Agency, a trusted provider of in-home senior care services, today announced its continued and unwavering commitment to the families and elderly residents of Harrisburg, NC. The agency reaffirms its mission to deliver high-quality, compassionate care, enabling seniors to live comfortably and independently in their own homes. This reaffirmation comes at a crucial time when accessible and reliable care is more important than ever for the community.
One of the primary benefits of the services offered by EULA Home Care Agency is the creation of personalized care plans tailored to each individual's unique needs and requirements. Recognizing that every senior has different requirements, the agency's professional caregivers provide support ranging from assistance with daily living activities, such as bathing and meal preparation, to medication reminders and mobility support. This customized approach to senior care in Harrisburg, NC, not only ensures the physical safety and well-being of clients but also promotes a greater sense of independence and dignity.
Furthermore, the agency provides invaluable peace of mind for families. Entrusting the care of a loved one to a professional can be a difficult decision, but EULA Home Care Agency alleviates this stress by offering reliable, vetted, and compassionate caregivers. Families can rest assured that their senior relatives are receiving exceptional Harrisburg senior home care, allowing family caregivers to get much-needed respite, reduce burnout, and spend more quality time with their loved ones without the constant pressure of caregiving responsibilities.
"Our mission has always been deeply rooted in the community we serve," said Davetta Williams, founder of EULA Home Care Agency. "We believe every senior deserves to age with dignity and grace in the comfort of their own home. We are here to ensure that families in Harrisburg know they have a reliable partner to turn to for compassionate and skilled care, making the aging process a smoother and more positive experience for everyone involved."
As the senior population in the region continues to grow, the need for dependable in-home care services has become increasingly evident. EULA Home Care Agency addresses this demand by focusing on a holistic approach that supports not only the physical health of seniors but also their emotional and social well-being. By providing companionship and fostering genuine connections, their caregivers help combat the loneliness and isolation that many seniors can experience.
EULA Home Care Agency remains dedicated to being a pillar of support for the Harrisburg community. By continuing to offer accessible and professional services, the agency ensures that local families have a trusted resource for senior care. Families seeking more information about the services provided are encouraged to visit the agency's website or call their office directly to schedule a complimentary consultation.
For more information about EULA Home Care Agency and their senior home care in Harrisburg, NC, please visit their website at https://eulahomecare.com
About EULA Home Care Agency:
EULA Home Care Agency is a premier provider of non-medical, in-home care services for seniors in Harrisburg, NC, and the surrounding areas. Founded by Davetta Williams, the agency is dedicated to delivering compassionate, professional, and personalized care that enables seniors to live safely and comfortably in their own homes.
Media Contact
Company Name: EULA Home Care Agency
Contact Person: Davetta Williams
Email: Send Email
Phone: +1 704 549 8300
Address: 8430 University Executive Park Dr Suite 606
City: Charlotte
State: NC
Country: United States
Website: http://www.eulahomecare.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Pulmatrix (PULM) Q2 Revenue Falls 100%
Key Points GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a substantial reduction in R&D activity. Pulmatrix focused on finalizing its merger with Cullgen and pursuing asset divestitures; no forward financial guidance was provided. These 10 stocks could mint the next wave of millionaires › Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025. Net loss per share (GAAP) was $(0.42), compared to $(1.59) in Q2 2024. There were no Wall Street analyst estimates available this quarter, but the reported GAAP loss per share of $(0.42) represented a substantial narrowing from last year's GAAP result of $(1.59) in Q2 2024, mainly due to a near-total reduction in research and development spending. The quarter highlights Pulmatrix's strategic pivot: winding down its prior clinical business, trimming operational costs, conserving cash, and focusing on completing its merger with Cullgen. The company offered no forward guidance for upcoming quarters as it transitions operations. Business Overview and Recent Areas of Focus Pulmatrix's core business has centered on developing inhaled therapies using its proprietary iSPERSE™ technology—a dry powder drug delivery platform aimed at improving medication delivery to the lungs. This platform was designed to increase efficiency and tolerability in treatments compared to traditional inhalers or oral medications, positioning the company in the respiratory therapeutics space. Over the past year, Pulmatrix's strategic priorities have shifted dramatically. It has halted most clinical operations, halted R&D spending, and now seeks to divest its iSPERSE™ intellectual property and remaining clinical assets. The company's ongoing viability depends on successfully completing its pending merger with Cullgen and monetizing its assets or securing royalty streams from former drug candidates such as PUR1900. Key success factors now rest less on product development and more on the execution of these strategic transactions. Quarter Highlights: Operations, Finances, and Pipeline Progress The quarter reflected a sharp operational downsizing as Pulmatrix's GAAP revenue dropped from $1.6 million in Q2 2024 to zero. This change resulted from the completion of the wind-down of its PUR1900 clinical trial. Former sources of operating income, such as milestone payments or funding for joint studies, concluded, and there were no new business or sales streams to replace them during the period. Research and development expense (GAAP) decreased from $2,834,000 in Q2 2024 to $14,000, a 99.5% drop. This near-total reduction in research spending came as Pulmatrix finished closing its flagship clinical programs and terminated related staff. The company stated: 'The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.' Helped by layoffs and cuts, although these savings were partially offset by legal and advisory expenses linked to the merger process. Net loss and operating loss (GAAP) both narrowed substantially. The reduced losses were primarily due to a sharp decrease in R&D expenses. Net loss (GAAP) dropped to $(1.55) million from $(5.81) million in Q2 2024. The company avoided any unusual charges this quarter, whereas the prior period had included a significant loss from an asset transaction with MannKind. With its extreme cost containment, Pulmatrix exited the quarter with a GAAP cash and cash equivalents position of $5.8 million (down from $9.5 million at December 31, 2024), which management expects will fund operations until the Cullgen merger is finalized. This period also saw Pulmatrix focus on two main strategic moves apart from operational cuts: the attempted sale of its iSPERSE™ intellectual property and clinical programs, and its merger with Cullgen. The company openly stated, 'Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.' These pipeline programs include PUR3100 for acute migraine (an orally inhaled dihydroergotamine engineered with iSPERSE™), PUR1800 for chronic obstructive pulmonary disease (a kinase inhibitor also using the iSPERSE™ platform), and PUR1900 (an inhaled formulation of an antifungal, developed with Cipla). Development or commercial responsibility for these candidates has ended or shifted to partners, and Pulmatrix itself has no ongoing clinical trials. Regulatory milestones from past years continued to carry some legacy value. For example, the Food and Drug Administration had accepted a Phase 2 study for PUR3100 and Pulmatrix's partner Cipla is moving forward with Phase 3 for PUR1900 in India. Pulmatrix may be eligible to receive a 2% royalty on possible future non-U.S. sales of PUR1900, but this would only occur if the product is successfully commercialized—a long-term and uncertain proposition. The most critical development during the second quarter was continued progress toward completing the merger with Cullgen, a protein degrader drug development company. Pulmatrix received stockholder approval and had its registration statement declared effective by the Securities and Exchange Commission. The merger remains contingent on regulatory approvals, including from the China Security Regulatory Commission and Nasdaq. Until the deal closes, Pulmatrix is in a holding pattern, and the company highlights that any delay or failure in closing poses significant risks to its ongoing viability. Looking Ahead: Guidance and Watchpoints Pulmatrix did not provide any financial guidance or operational outlook for the next quarter or upcoming year. No revenue or earnings forecast was offered by management in the latest earnings release. The company's leadership made clear that the near-term objective is to complete the planned merger and monetize or transfer its remaining assets. Because Pulmatrix is not currently developing or selling any medications, its short-term future is heavily dependent on successful asset divestitures and getting the Cullgen deal across the finish line. Investors and observers should monitor progress toward merger closing, potential updates on the sale of iSPERSE™-related patent portfolios, and any royalty developments with former pipeline candidates. PULM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
3 hours ago
- CTV News
Union sounding alarm on home-care changes
Union sounding alarm on home-care changes New changes for home care scheduling are creating challenges for nurses and families. CTV's Danton Unger reports.
CBC
3 hours ago
- CBC
RFK Jr.'s move to axe $500M in vaccine funding slammed
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has announced a $500-million cut to funding for mRNA vaccine development, insisting the technology used in COVID-19 vaccines poses risks. Many medical experts say the reasoning is untrue and could slow development of future vaccinations.
